Riskpilot← Back to searchSign inGet full accessMediagnos AB
ABActiveOrg 5567997217Magnebergsvägen 6Activities of advertising agencies · NACE 7311Est. 20100 employees
Revenue 2025
SEK 51K
-69% vs 2024
EBITDA margin
-260.7%
+37% vs 2024
Equity ratio
91.2%
Financial strength
Net profit 2025
SEK -141K
+19% vs 2024
| Revenue | SEK 51K | -69% |
| EBITDA | SEK -134K | +37% |
| Net profit | SEK -141K | +19% |
| Total assets | SEK 400K | -27% |
| Equity | SEK 365K | -28% |
| Employees | 0 | — |
Legal name
Mediagnos AB
Org number
5567997217
Legal form
Aktiebolag
NACE code
7311 · Activities of advertising agencies
Founded
21 januari 2010
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktibolagets verksamhet ska vara att bedriva konsult- och ut- bildningsverksamhet inom media och journalistik. Bolaget skall även utföra musiktjänster samt därmed jämförliga verksamheter.
Address
Magnebergsvägen 6
Phone
+46708913850
Email
johan.holm@mediagnos.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 603 | 672 | 200 | 163 | 51 |
| Staff expenses | — | −253 | −253 | −263 | −101 |
| EBITDA | 83 | 323 | −139 | −213 | −134 |
| Depreciation & amort. | −0 | — | — | — | −7 |
| EBIT | 83 | 323 | −139 | −213 | −141 |
| Net financials | — | — | 0 | 0 | 1 |
| Profit before tax | 63 | 242 | 6 | −173 | −141 |
| Tax | −14 | −50 | −4 | — | — |
| Net profit | 49 | 191 | 2 | −173 | −141 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 660 | 961 | 727 | 545 | 400 |
| Equity | 484 | 676 | 678 | 505 | 365 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 72 | 100 | 8 | 40 | 35 |
| Total debt | 72 | 100 | 8 | 40 | 35 |
EBITDA margin
-260.7%
This company
15.8%
Market median
-1750% vs market
20212025
Equity ratio
91.2%
This company
38.2%
Market median
+139% vs market
20212025
Return on equity
-38.5%
This company
18.4%
Market median
-309% vs market
20212025
Net profit margin
-273.0%
This company
8.1%
Market median
-3470% vs market
20212025
Asset turnover
0.13×
This company
1.12×
Market median
-88% vs market
20212025
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mediagnos AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Margareta Ulrika Sundström | Deputy Board Member | 0 companies |
| Johan Magnus Holm | Board of Directors | 0 companies |